Dianthus Therapeutics (DNTH) Non-Current Deffered Revenue (2018 - 2025)
Historic Non-Current Deffered Revenue for Dianthus Therapeutics (DNTH) over the last 7 years, with Q3 2025 value amounting to $6.1 million.
- Dianthus Therapeutics' Non-Current Deffered Revenue rose 84812.5% to $6.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.1 million, marking a year-over-year increase of 84812.5%. This contributed to the annual value of $1.9 million for FY2024, which is 15923.91% up from last year.
- Latest data reveals that Dianthus Therapeutics reported Non-Current Deffered Revenue of $6.1 million as of Q3 2025, which was up 84812.5% from $1.8 million recorded in Q2 2025.
- In the past 5 years, Dianthus Therapeutics' Non-Current Deffered Revenue ranged from a high of $6.1 million in Q3 2025 and a low of $640000.0 during Q3 2024
- Its 4-year average for Non-Current Deffered Revenue is $1.6 million, with a median of $768000.0 in 2022.
- As far as peak fluctuations go, Dianthus Therapeutics' Non-Current Deffered Revenue plummeted by 1409.4% in 2024, and later surged by 84812.5% in 2025.
- Quarter analysis of 4 years shows Dianthus Therapeutics' Non-Current Deffered Revenue stood at $791000.0 in 2022, then decreased by 6.95% to $736000.0 in 2023, then soared by 159.24% to $1.9 million in 2024, then soared by 218.03% to $6.1 million in 2025.
- Its last three reported values are $6.1 million in Q3 2025, $1.8 million for Q2 2025, and $1.9 million during Q1 2025.